| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Departments of Immunohematology and Blood Transfusion [M. J. P. W., A. d. J., S. J. F. v. d. E., J. M. v. d. H., K. M. C. K., S. H., K. L. M. C. F., J. W. D., C. J. M. M., R. O., S. H. v. d. B.], Clinical Pharmacy and Toxicology [A. d. J.], Gynecology [G. K.], and Pathology [G. J. F.], Leiden University Medical Center, 2333 ZA Leiden, the Netherlands
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-ELISPOT assay. Although nearly all E6-peptides were recognized, the majority of the responders targeted peptide sequences of the COOH-terminal half (E681–158) of HPV-16 E6. In a direct comparison, the presence of HPV-16 E6-specific T cells coincided with HPV-16 E2-specific T-cell reactivity in healthy individuals, whereas hardly any HPV-16 E7-specific Th immunity was found. This indicates that the induction of T-cell reactivity against HPV-16 E7 is suboptimal during infection when compared with that against HPV-16 E2 and HPV-16 E6. In conclusion, the presence of HPV-16 E6-specific Th memory in the healthy population demonstrates that HPV infection leads to T-cell immunity against immediate early proteins expressed during infection. Because this HPV-16 E6-specific T-cell immunity was frequently detected in healthy subjects, our data suggest that the observed IFN--producing proliferating T cells circulating in the peripheral blood play a role in protection against persistent HPV infection and associated development of malignancies. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Examination of HPV-specific T-cell immunity in patients with HPV+ cervical lesions has revealed the occasional presence of CTL responses against the E6 and E7 oncoproteins (13, 14, 15, 16, 17, 18) . Because an overt correlation between the presence of such CTL immunity and regression or progression of the disease has thus far not been found, the functional significance of these responses is at present a matter of debate. Most likely, not only CTL numbers, but also their activation state needs to be taken into account. Accumulating evidence pertinently shows that proper activation of CTL requires delivery by professional APCs of strong costimulatory signals in addition to the antigenic signal. Especially in the case of antiviral immunity in chronic infections, this costimulatory action of APC requires virus-specific Th cell activity (19, 20, 21, 22, 23) . We previously found that E7-specific Th immunity was frequently observed in HPV-16+ patients but only rarely in healthy subjects (24) . In contrast, >50% of the healthy subjects tested showed very strong memory-type Th responses against one or more epitopes of HPV-16 E2. It is conceivable that this Th memory is a witness of previous encounter with HPV-16 or possibly other HPV-types encoding cross-reactive epitopes (25) . Apparently, the T-cell immune system deals with the E2 and E7 antigens in a completely different manner. Because high expression of E6/E7 and E2 is mutually exclusive during infection and subsequent tumor development, these findings prompted us to now also monitor Th immunity against HPV-16 E6 in patients and healthy subjects. Similar to what was found for E2, memory Th immunity against E6 was frequently and abundantly observed in healthy subjects, suggesting a role for these Th cells in protection against reinfection by high-risk HPV and as such the HPV-mediated induction of anogenital lesions and cervical cancer.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The study of the subjects (P) with cervical carcinoma in this paper was nested in the CIRCLE study, which investigates cellular immunity against HPV-16-infected cervical lesions. Women presenting with histological proven cervical carcinoma at the department of gynecology of the Leiden University Medical Center were, after informed consent, enrolled in this study. The study design was approved by the Medical Ethical Committee of the Leiden University Medical Center. Blood was drawn at day of treatment before surgery. Subjects with stage IB-IIA were treated by a radical hysterectomy. The age of the patients ranged between 29 and 76 years old, and these women were typed for HPV-16 using HPV-16-specific primers on DNA isolated from paraffin-embedded sections of biopsies or surgical resection specimens (26) .
Antigens.
A set of peptides spanning the whole HPV-16 E2 protein, consisting of 22 30-mer peptides with 15 amino acids of overlap and the COOH-terminal peptide with a length of 35 amino acids, was used for the T-cell proliferation assays. They are indicated by the first and last amino acid in the protein (e.g., E21–30, residues 1–30, and the last peptide E2331–365). For the ELISPOT assays, a large set of 22-residue long HPV-16 E6 overlapping (12 residues) peptides was used to obtain a detailed insight in the immunogenic regions of the E6 protein. In addition, 8 HPV-16 E6-derived 32-mer overlapping (14 residues) peptides and 4 HPV-16 E7 35-mer overlapping (14 residues) peptides were used for the T-cell cultures and proliferation assays. These long HPV-16 E2, HPV-16 E6, and HPV-16 E7 peptides were used in the proliferation assay to lower the number of PBMCs required because we wanted to use pools of maximal two peptides.
Pools of four 30-mer peptides, with 15 amino acids overlap, spanning the influenza matrix 1 protein of A/PR/8/34 (M1) were used as positive control in the ELISPOT assay. The peptides were synthesized and dissolved as described previously (27) .
TT (1 LF/ml; National Institute of Public Health and the Environment, Bilthoven, the Netherlands) was used as positive control in the short-term T-cell proliferation assays.
Recombinant HPV-16 E6 protein and HPV-16 E7 protein (the latter protein served as control protein in proliferation assays) were produced in recombinant Escherichia coli transformed with Pet-19b-HPV-16 E6 and Pet-19b-HPV-16 E7 (24) .
Analysis of Antigen-specific Th Cells by IFN--ELISPOT.
The presence of HPV-16 E6-specific Th cells was analyzed by ELISPOT as described previously (24)
. Briefly, PBMCs were seeded at a density of 2 x 106 cells/well of a 24-well plate (Costar, Cambridge, MA) in 1 ml of Iscove’s medium (Bio-Whittaker, Verviers, Belgium) enriched with 10% FCS (Greiner, Mannheim, Germany) in the presence or absence of 5 µg/ml of indicated E6-derived 22-mer peptide. As a positive control, PBMCs were cultured in the presence of indicated pools of influenza A/PR/8/34 M1 protein-derived peptides, consisting of four overlapping 30 amino acid long peptides in each pool because previous analyses showed that all healthy individuals displayed reactivity against one or more of these M1 peptide pools (24)
. After 4 days of incubation at 37°C, PBMCs were harvested, washed, and seeded in 6-replicate wells at a density of 105 cells/well on a Multiscreen 96-well plate (Millipore, Etten-Leur, the Netherlands) coated with an IFN- catching antibody (Mabtech AB, Nacha, Sweden). Then, the ELISPOT plates were incubated for 18 h at 37°C to allow catching of the antigen-specific produced IFN-. The ELISPOT assay was additionally performed according to the instructions of the manufacturer (Mabtech). The number of spots was analyzed with a fully automated computer-assisted video imaging analysis system (Carl Zeiss Vision). Specific spots were calculated by subtracting the mean number of spots plus 2x SD of the medium only control from the mean number of spots of experimental wells. Antigen-specific T-cell frequencies were considered to be increased compared with nonresponders when T-cell frequencies were 
1/104 PBMCs (24)
.
Short-Term T-Cell Proliferation Assay.
Healthy donor-derived PBMCs were incubated with 12 pools of HPV-16 E2-derived 30-mer peptides, 4 pools of E6 32-mer peptides, and 2 pools of E7 35-mer peptides (each pool containing two overlapping peptides), according to procedures described previously (25
, 27)
. Briefly, freshly isolated PBMCs were seeded at a density of 1.5 x 105 cells/well in a 96-well U-bottomed plate (Costar, Cambridge, MA) in 200 µl of Iscove’s medium (Bio-Whittaker) supplemented with 10% autologous serum. In previous experiments, we observed that proliferative responses to HPV-16 E2 peptides were relatively reduced with the use of (heat-inactivated) human AB serum (Sigma) as compared with autologous serum. HPV-16 E2-, HPV-16 E6- and HPV-16 E7-derived peptides were added at a concentration of 10 µg/ml. Medium alone was taken along as a negative control and TT served as a positive control. For each peptide pool, 8 parallel microcultures were incubated. Peptide-specific proliferation was measured at day 6 by [3H]thymidine incorporation. Cultures were scored positive when the proliferation of 75% of the test wells exceeded the mean proliferation plus 3x SD of the medium only control wells, and the SI of the mean test wells over mean medium control wells was 3.
Long-Term HPV-16 E6-specific T-Cell Cultures.
PBMCs derived from healthy blood donors were incubated with 8 overlapping 32-mer peptides spanning the entire HPV-16 E6 protein at a concentration of 1 µg/ml in Iscove’s medium (Bio-Whittaker) supplemented with 10% recalcified autologous plasma. One day after stimulation, T-cell growth factor (Biotest, Dreieich, Germany) was added at a final concentration of 5%. At day 10, the cell culture was harvested and incubated with autologous monocytes and E6 peptides (1 µg/ml) at a 10:1 ratio for 16 h, after which, T cells producing IFN- in response to the E6 peptides were enriched by a cytokine secretion assay (Miltenyi; Biotech, Bergisch Gladbach, Germany). This assay is based on a bispecific antibody recognizing (a) the IFN- molecule and (b) the CD45 molecule. The captured IFN- is detected by a phycoerythrin-labeled secondary antibody, and subsequent magnetic labeling allows enrichment of the antigen-specific cells. The isolated cells were cultured for 10–14 days with irradiated autologous PBMCs at 1:10 ratio and 10% T-cell growth factor without any further addition of antigen. The polyclonal T-cell culture was tested for recognition of E6 peptides (5 µg/ml) and protein (10 µg/ml) in a 3-day proliferation assay. Autologous adherent monocytes were used as APCs, and proliferation was measured by [3H]thymidine incorporation.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-secreting Th Cells in HPV-16-positive Cervical Cancer Patients.-producing E6-specific Th cells was determined by ELISPOT. In 3 of 11 HPV-16+ patients (P4, P5, and P8), HPV-16 E6-specific Th frequencies 1/10,000 PBMCs were demonstrated. On the basis of our experience, responses of such a magnitude are clearly positive, whereas responses lower than this frequency may fall within background reactivity (24)
. Patient P4 responded to peptide E631–52 and E6131–152, indicating the presence of memory Th cells specific for two distinct epitopes. The other two patients (P5 and P8) responded to only one E6 peptide, suggesting that in both cases a single E6-epitope was recognized (Table 1)
. Overall, the frequency and magnitude of Th1-type response against E6 detected in patients is comparable with that previously found for E7 (24)
.
|
. Analysis of the reactivity pattern revealed that most responses detected were directed against peptide sequences of the COOH-terminal half (E681–158) of HPV-16 E6 (Table 1)
. The magnitude of the E6-specific responses was very similar to that found in patients. However, the fraction of healthy donors showing strong IFN- Th responses against E6 peptides appears higher than that of the patients (60 versus 27%). Furthermore, some of the healthy subjects reacted even against four or more E6-peptides (range, 1–7), whereas the 3 patients responded to one or two peptides only. It must be noted, however, that also the incidence and breadth of the response against the influenza M1 antigen is higher in healthy subjects (Table 1)
, indicating an overall reduced immunity in patients.
To further characterize the observed HPV-16 E6-specific IFN--responses in healthy subjects, the E6-induced proliferation capacity of PBMCs was analyzed. Freshly isolated PBMCs of 5 healthy donors were stimulated with a pool of eight of the long 32-mer overlapping HPV-16 E6-peptides for 10 days, and the responding T cells were isolated based on the E6-specific IFN- production using cytokine secretion assay and magnetic cell sorting. Flow cytometric analysis of the T cells specifically responding to E6 revealed that these T cells resided in the CD4+ fraction only (Fig. 1)
. After a 14-day period of nonspecific expansion, the resulting T-cell cultures were tested for their proliferative capacity to both E6 peptides and E6 protein because the latter will indicate their capacity to respond to naturally processed and presented antigen. From 3 of these 5 cultures, we were able to isolate IFN--producing HPV-16 E6-specific Th cells able to proliferate not only upon stimulation with peptide but also to E6 protein-pulsed APCs (Fig. 1)
. Two subjects (D21 and D23) predominantly responded to E673–109 and E6127–158, whereas the third donor (D22) displayed a broader reaction pattern (Fig. 1)
. The area covered by E673–109 and E6127–158 was also frequently recognized when the E6 response was analyzed by ELISPOT (Table 1)
. Taken together, our data demonstrate that the memory T-cell repertoire of the majority of healthy individuals contains proliferative and IFN--producing CD4+ Th-cells capable of reacting against the HPV-16-derived E6 oncoprotein.
|
; Ref. 25
). One donor (D33; Fig. 2
) displayed responses against all three antigens, and 3 donors [D27 (Fig. 2)
, D30, and D37] showed specific proliferation against E2 and E6 (Table 2)
. In three other cases (D26, D29, D34) responses were only found against E2, whereas one PBMC sample (D31) only responded to E6 peptides. Most importantly, a vast majority (8 of 12) of the healthy subjects displayed memory-type Th responses against HPV-16 E2 and/or HPV-16 E6 in their blood, supporting the notion that encounter with high-risk HPV types, including HPV-16, is very common (1, 2, 3)
. Although in certain cases, this event may result in the prevalence of Th memory against either E2 or E6 rather than against both antigens; such immunity against the E7 antigen is only rarely installed (Table 2
, Fig. 2
).
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-ELISPOT and short-term proliferation assays. Isolated E6 peptide-specific Th cells from such healthy subjects specifically reacted upon stimulation with HPV-16 E6 protein showing their capacity to respond not only to peptide but also to naturally processed HPV-16 E6 protein. Because E6 protein sequences are conserved to considerable extent between HPV types, it is conceivable that infection with a given HPV type induces T cells, which are also able to react with peptides of HPV-16. Amino acid sequence analysis revealed that especially the genital high-risk HPV types displayed strong homology with HPV-16 E6 (data not shown). Therefore, part of the memory Th responses measured in this study might be a reflection of previous infections with high-risk HPV types other than HPV-16. Furthermore, the relatively high incidence and prevalence of (subclinical) infection with high-risk HPV (3 , 6 , 28) implies that some of these responses reflect current HPV infection.
In PBMCs from patients diagnosed with HPV-16+ cervical carcinoma, E6-specific Th type 1 immunity was detected in 
30% (3 of 11) of the patients tested. As such, the number of E6-specific responders does not differ from that of HPV-16+ patients with E7-specific Th type 1 reactivity (6 of 16, 40%; Ref. 24
and unpublished observations). On the basis of the frequency of E6 responses in healthy individuals, the HPV-16 E6-specific Th cells in patients are likely to represent the remnants of a failing immune response, whereas Th reactivity to E7 may reflect de novo responses after cross-priming of E7 derived from a progressive tumor. Interestingly, a direct comparison of Th responses against HPV-16 E6 and HPV-16 E7 in healthy individuals reveals a different trend of immune activity. Only 1 of 12 healthy blood donors displayed E7-specific Th immunity, whereas 5 of these 12 healthy subjects reacted upon stimulation with HPV-16 E6 peptides. Moreover, we demonstrated that E6-specific Th responses in general coincided with responses against HPV-16 E2. In addition, if one takes into account that probably not all of these anonymous healthy blood donors have encountered HPV-16, whereas the patients are all HPV-16+, the percentage of healthy subjects responding to HPV-16 E6 after successful clearance of the HPV infection is likely to be underestimated. Failure of boosting the E6-specific Th1 type immunity may thus be related to progressive infection, which was also suggested by the work of Kadish et al. (31)
. To address this, a more comprehensive study of HPV-16-specific immunity in relation to disease and HPV infection status is required.
Collectively, our data suggest that the induction of Th cell reactivity against the HPV-16 E7 protein is suboptimal when compared with that against HPV-16 E2 and HPV-16 E6. Recently, it was shown that CD4+ T-cell reactivity against the plantar wart causing low-risk HPV type 1 was predominantly directed against the E4 protein (50%) and to a lesser extent against E6 (20%). Th-cell reactivity against HPV-1 E7, like our results with HPV-16 E7, could not be demonstrated (32) . Presently, it is not clear why Th reactivity is preferentially induced against the HPV-16 E6 protein and not against E7. Because of the nature of HPV infection, induction of T-cell immunity is exclusively dependent on cross-presentation by epithelial resident dendritic cells, the Langerhans cell (33) . Possibly, the localization of the antigen in the infected cell may determine the accessibility of these antigens for Langerhans cells. Low-risk and high-risk E7 proteins are expressed in the nucleus of the cell (34) , and Th responses against this antigen are hardly detected in healthy subjects (24 , 32) . The expression of HPV-1 E4 protein is predominantly cytoplasmic, and a large fraction of healthy subjects mount an HPV-1 E4-specific Th response (32) . Interestingly, the expression of low-risk HPV E6 protein is also restricted to the nucleus, but E6 of high-risk HPV is expressed in the nucleus and the cytoplasm (34) . This difference in localization seems to be reflected by the low Th response rate against HPV type 1 E6 protein and the frequent induction of HPV-16 E6-specific Th reactivity in healthy subjects. Moreover, the similar cytoplasmic and nuclear expression of HPV-16 E2 induces Th memory in healthy individuals (25 , 35) .
In conclusion, the high rate of spontaneous clearance of high-risk HPV infections suggests that in general, the Langerhans cell-driven antigen presentation machinery is capable of inducing an effective immune defense against HPV. Our study is the first to demonstrate the presence of HPV-16 E6-specific memory Th immunity in the healthy population and shows that HPV infection indeed leads to T-cell immunity against the (immediate) early proteins E2 and E6 expressed during infection. Because the population, in which E2- and E6-specific T-cell immunity frequently is found, consists of healthy subjects, the observed IFN--producing T cells circulating in the peripheral blood may play a role in protection against newly and/or persistent HPV infections and as such the development of cancer.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 This work was supported by Dutch Cancer Society Grants NKB:RUL 99–2024 and RUL 2000–2200 (to R. O. and C. J. M. M.) and a grant from the Cancer Research Institute (to S. H. v. d. B.). 
2 Both authors contributed equally to this article.
3 To whom requests for reprints should be addressed, at Department of Immunohematology and Blood Transfusion, Building 1, E3-Q, Leiden University Medical Center, P. O. Box 9600, 2300 RC Leiden, the Netherlands. Phone: 31-71-5264007; Fax: 31-71-5216751; E-mail: shvdburg{at}worldonline.nl
4 The abbreviations used are: HPV, human papillomavirus; APC, antigen-presenting cell; ELISPOT, enzyme-linked immunospot; M1, influenza matrix 1 protein; PBMC, peripheral blood mononuclear cell; SI, stimulation index; Th, T-helper; TT, tetanus toxoid.
Received 7/10/02. Accepted 12/ 2/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
interferon release. J. Virol., 76: 6027-6036, 2002.This article has been cited by other articles:
|
|
 |
|
  G. G. Kenter, M. J.P. Welters, A. R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia N. Engl. J. Med., November 5, 2009; 361(19): 1838 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Karim, E. S. Jordanova, S. J. Piersma, G. G. Kenter, L. Chen, J. M. Boer, C. J. M. Melief, and S. H. van der Burg Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma Clin. Cancer Res., October 15, 2009; 15(20): 6341 - 6347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Trimble, S. Peng, F. Kos, P. Gravitt, R. Viscidi, E. Sugar, D. Pardoll, and T.C. Wu A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3 Clin. Cancer Res., January 1, 2009; 15(1): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. de Vos van Steenwijk, S. J. Piersma, M. J.P. Welters, J. M. van der Hulst, G. Fleuren, B. W.J. Hellebrekers, G. G. Kenter, and S. H. van der Burg Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response Clin. Cancer Res., November 15, 2008; 14(22): 7188 - 7195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D S Hughes, N Powell, and A N Fiander Will vaccination against human papillomavirus prevent eye disease? A review of the evidence Br J Ophthalmol, April 1, 2008; 92(4): 460 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Kenter, M. J.P. Welters, A.R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, et al. Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity Clin. Cancer Res., January 1, 2008; 14(1): 169 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J.P. Welters, G. G. Kenter, S. J. Piersma, A. P.G. Vloon, M. J.G. Lowik, D. M.A. Berends-van der Meer, J. W. Drijfhout, A. R. P.M. Valentijn, A. R. Wafelman, J. Oostendorp, et al. Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine Clin. Cancer Res., January 1, 2008; 14(1): 178 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Seresini, M. Origoni, F. Lillo, L. Caputo, A. M. Paganoni, S. Vantini, R. Longhi, G. Taccagni, A. Ferrari, C. Doglioni, et al. IFN-{gamma} Produced by Human Papilloma Virus-18 E6-Specific CD4+ T Cells Predicts the Clinical Outcome after Surgery in Patients with High-Grade Cervical Lesions J. Immunol., November 15, 2007; 179(10): 7176 - 7183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. van der Burg, S. J. Piersma, A. de Jong, J. M. van der Hulst, K. M. C. Kwappenberg, M. van den Hende, M. J. P. Welters, J. J. Van Rood, G. J. Fleuren, C. J. M. Melief, et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens PNAS, July 17, 2007; 104(29): 12087 - 12092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. E. Gallagher and S. Man Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women J. Gen. Virol., May 1, 2007; 88(5): 1470 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. Kim, W. Greenfield, E. Shotts, and M. Nakagawa Detection of Human Papillomavirus Type 16-Specific T Lymphocytes by a Recombinant Vaccinia Virus-Based Enzyme-Linked Immunospot Assay Clin. Vaccine Immunol., April 1, 2007; 14(4): 362 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Piersma, E. S. Jordanova, M. I.E. van Poelgeest, K. M.C. Kwappenberg, J. M. van der Hulst, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, G. J. Fleuren, R. Offringa, et al. High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer Cancer Res., January 1, 2007; 67(1): 354 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I.E. van Poelgeest, M. van Seters, M. van Beurden, K. M.C. Kwappenberg, C. Heijmans-Antonissen, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, T. J.M. Helmerhorst, R. Offringa, et al. Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment Clin. Cancer Res., July 15, 2005; 11(14): 5273 - 5280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Smith, A. Tristram, K. M. Gallagher, A. N. Fiander, and S. Man Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18 Int. Immunol., February 1, 2005; 17(2): 167 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Preville, D. Ladant, B. Timmerman, and C. Leclerc Eradication of Established Tumors by Vaccination With Recombinant Bordetella pertussis Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein Cancer Res., January 15, 2005; 65(2): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. de Jong, M. I. E. van Poelgeest, J. M. van der Hulst, J. W. Drijfhout, G. J. Fleuren, C. J. M. Melief, G. Kenter, R. Offringa, and S. H. van der Burg Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 Cancer Res., August 1, 2004; 64(15): 5449 - 5455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. DeVoti, B. M. Steinberg, D. W. Rosenthal, L. Hatam, A. Vambutas, A. L. Abramson, M. J. Shikowitz, and V. R. Bonagura Failure of Gamma Interferon but Not Interleukin-10 Expression in Response to Human Papillomavirus Type 11 E6 Protein in Respiratory Papillomatosis Clin. Vaccine Immunol., May 1, 2004; 11(3): 538 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Chaturvedi, J. A. Brinkman, A. M. Gaffga, J. Dumestre, R. A. Clark, P. S. Braly, K. Dunlap, P. J. Kissinger, and M. E. Hagensee Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women J. Gen. Virol., May 1, 2004; 85(5): 1237 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. C. Smyth, M. I. E. van Poelgeest, E. J. Davidson, K. M. C. Kwappenberg, D. Burt, P. Sehr, M. Pawlita, S. Man, J. K. Hickling, A. N. Fiander, et al. Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination Clin. Cancer Res., May 1, 2004; 10(9): 2954 - 2961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Baldwin, S. H. van der Burg, C. M. Boswell, R. Offringa, J. K. Hickling, J. Dobson, J. St. C. Roberts, J. A. Latimer, R. P. Moseley, N. Coleman, et al. Vaccinia-Expressed Human Papillomavirus 16 and 18 E6 and E7 as a Therapeutic Vaccination for Vulval and Vaginal Intraepithelial Neoplasia Clin. Cancer Res., November 1, 2003; 9(14): 5205 - 5213. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
) represents proliferation in each individual microculture, and the (